The Unintended Consequences of Small Molecules
2024-03-14
抗体药物偶联物
Continuing on from our previous episode "The Gap is Where the Pain Is", this episode focuses on a healthy discussion regarding the IRA, particularly the unintended consequences to small molecule development within the industry and for patients.
Topics explored in this discussion are potential reasons behind the small molecule negotiation timeline decision, the antibody drug conjugates (ADC) boom, the investment environment, and positive steps the government is making through legislation to equalize the negotiation timeline.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Ali Pashazadeh, CEO,Treehill Partners
Dan Smithey, President, CEO and Co-founder, Serán BioScience
Matthew Price, COO and Co-founder, Promontory Therapeutics
Peter Rubin, Executive Director, No Patient Left Behind
Rob Williamson, President and COO, Triumvira Immunologics
> Listen on Spotify
> Listen on Apple podcasts
> Listen on Amazon Music
> Listen on iHeart
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-药物
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。